Page 5 - Nasdaq Allo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrates Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...

Long Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials Demonstrate Potential of Allogeneic CD19 CAR T to Generate Durable Complete Responses Similar to...

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have given a buy recommendation to the […]

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) dropped 7.3% on Tuesday . The stock traded as low as $6.22 and last traded at $6.25. Approximately 343,732 shares changed hands during trading, a decline of 82% from the average daily volume of 1,961,051 shares. The stock had previously closed at $6.74. Analyst Ratings Changes ALLO has […]

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) had its price target reduced by Stifel Nicolaus from $8.00 to $7.50 in a research note released on Thursday, The Fly reports. Several other research analysts also recently commented on ALLO. Robert W. Baird raised shares of Allogene Therapeutics from a neutral rating to an outperform rating and set […]